Novartis AG
Dose and regimen for HDM2-p53 interaction inhibitors
Last updated:
Abstract:
The present invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer, wherein the drug is administered by a high dose intermittent dosing regimen. The present invention relates in particular to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4 week cycle.
Status:
Grant
Type:
Utility
Filling date:
14 Nov 2017
Issue date:
6 Apr 2021